Research and experimental development on natural sciences and engineering
MIM PHARMA AS
Revenue 2024
NOK 22
Operating profit
NOK −35,000
Equity
NOK −261,000
Incorporated
2013
Share capital
NOK 60,000
Key figures · 2024
Current ratio
1.94
Equity ratio
-443.4%
Key figures over time · 2024
| Key figures | 2024 | Trend |
|---|---|---|
| Lønnsomhet | ||
| Operating margin (%%) | -157559.1% | |
| Net margin (%%) | -157559.1% | |
| Return on assets (%%) | -58.9% | |
| Likviditet | ||
| Current ratio | 1.94 | |
| Working capital | 14k | |
| Soliditet | ||
| Equity ratio (%%) | -443.4% | |
| Debt-to-equity ratio | -1.23 | |
Source: Biztrac.no · Data from the Brønnøysund Register Centre and the Norwegian Tax Administration · Last updated 15.06.2026.